Key result
Given the substantial bleeding risks and lack of randomized data, the optimal scope and duration of antiplatelet treatment following left atrial appendage occlusion remains uncertain.
This editorial highlights the lack of randomized data for post-LAAC antiplatelet therapy and suggests that short-term dual antiplatelet therapy may be preferable to minimize bleeding risks in this high-risk population.
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Pracoń R, Demkow M. EditorialHow to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2015;11(1):5-8. doi:10.5114/pwki.2015.49177. APA Pracoń, R., & Demkow, M. (2015). EditorialHow to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 11(1), 5-8. https://doi.org/10.5114/pwki.2015.49177 Chicago Pracoń, Radosław, and Marcin Demkow. 2015. "EditorialHow to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 11 (1): 5-8. doi:10.5114/pwki.2015.49177. Harvard Pracoń, R., and Demkow, M. (2015). EditorialHow to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 11(1), pp.5-8. https://doi.org/10.5114/pwki.2015.49177 MLA Pracoń, Radosław et al. "EditorialHow to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 11, no. 1, 2015, pp. 5-8. doi:10.5114/pwki.2015.49177. Vancouver Pracoń R, Demkow M. EditorialHow to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2015;11(1):5-8. doi:10.5114/pwki.2015.49177.
No takes yet. Share an insight, caveat, or question.
Pracoń et al. (2015) conducted an editorial in Atrial fibrillation post left atrial appendage occlusion. Antiplatelet therapy was evaluated. Given the substantial bleeding risks and lack of randomized data, the optimal scope and duration of antiplatelet treatment following left atrial appendage occlusion remains uncertain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: